Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The analytical team have:

  • Shown that collider bias may explain recent high-profile claims that G6PD deficiency may
  • protect against cerebral malaria directly.
  • Using causal inference theory based on directed acyclic graphs that moderate anaemia protects against mortality in patients with severe malaria.
  • Developed a new approach to the interpretation of P. vivax recurrences that combines genotyping and time to event modelling, and allocates the cause of recurrence with a high degree of confidence.
  • Modelled the pharmacokinetic-pharmacodynamic relationships underlying toxicity of the newly registered sleeping sickness medicine fexinidazole. This was important in contributing to EMA approval in October 2018.